Gleason Pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation

International Journal of Radiation Oncology Biology Physics

Volumn 81, Issue 4, 2011, Pages

  Sabolch, Aaron ^a   Feng, Felix Y ^a,b,d   Daignault Newton, Stephanie ^a,c   Halverson, Schuyler ^a   Blas, Kevin ^a   Phelps, Laura ^a   Olson, Karin B ^a,b   Sandler, Howard M ^e   Hamstra, Daniel A ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Department of Radiation Oncology ^*  (United States)

^c Division of Biostatistics   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Gleason Pattern 5; Gleason score; Prostate cancer; Radiation therapy; Stratification

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; CAUSE-SPECIFIC SURVIVAL; CLINICAL FAILURE; CLINICAL OUTCOME; COMORBID ILLNESS; FREEDOM FROM BIOCHEMICAL FAILURES; GLEASON PATTERN 5; GLEASON SCORES; HAZARD RATIO; LOCALIZED PROSTATE CANCER; MULTI VARIATE ANALYSIS; OVERALL SURVIVAL; PLANNING TARGET VOLUMES; PRE-TREATMENT; PROGNOSTIC FACTORS; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; RISK FACTORS; RISK STRATIFICATION; SYSTEMIC THERAPY;

DISEASES; MULTIVARIANT ANALYSIS; PATIENT MONITORING;

RADIOTHERAPY;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING;

AGED; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RISK FACTORS; TREATMENT FAILURE;

EID: 80255137088     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.01.063     Document Type: Article

References (50)

1. M. Han, A. Partin, and C. Pound Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: The 15-year Johns Hopkins experience Urol Clin North Am 28 2001 555 565 (Pubitemid 32916759)
2. C. Pound, A. Partin, and M. Eisenberger Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591 1597 (Pubitemid 29211767)
3. T. Chan, A. Partin, and P. Walsh Prognostic significance of Gleason score 3+ 4 versus Gleason score 4+ 3 tumor at radical prostatectomy Urology 56 2000 823 827
4. J. Epstein, A. Partin, and J. Sauvageot Prediction of progression following radical prostatectomy: A multivariate analysis of 721 men with long-term follow-up Am J Surg Pathol 20 1996 286 292 (Pubitemid 26071509)
5. D. Kuban, H. Thames, and L. Levy Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era Int J Radiat Oncol Biol Phys 57 2003 915 928 (Pubitemid 37324109)
6. A. Pollack, L. Smith, and A. von Eschenbach External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era Int J Radiat Oncol Biol Phys 48 2000 507 512
7. T. Pisansky, M. Kahn, and G. Rasp A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma Cancer 79 1997 337 344 (Pubitemid 27029898)
8. J. Mohler, R. Bahnson, and B. Boston National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Prostate Cancer J Natl Compr Canc Neww 8 2010 162 200
9. A. Nanda, M. Chen, and A. Renshaw Gleason pattern 5 prostate cancer: Further stratification of patients with high-risk disease and implications for future randomized trials Int J Radiat Oncol Biol Phys 74 2009 1419 1423
10. R. Stock, J. Cesaretti, and S. Hall Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy BJU Int 104 2009 1631 1636
11. L. Cheng, D. Davidson, and H. Lin Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy Cancer 110 2007 1967 1972 (Pubitemid 350036855)
12. L. Cheng, M. Koch, and B. Juliar The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy J Clin Oncol 23 2005 2911 2917 (Pubitemid 46224109)
13. D. D'Ambrosio, A. Hanlon, and T. Al-Saleem The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 67 2007 1082 1087
14. T. Stamey, J. McNeal, and C. Yemoto Biological determinants of cancer progression in men with prostate cancer JAMA 281 1999 1395 1400 (Pubitemid 29190217)
15. A. Vis, S. Roemeling, and R. Kranse Should we replace the Gleason score with the amount of high-grade prostate cancer? Eur Urol 51 2007 931 939 (Pubitemid 46281411)
16. Kuban D, Levy L, Cheung M, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer: Who dies of disease? Int J Radiat Oncol Biol Phys. In press.
17. Z. Symon, K. Griffith, and P. McLaughlin Dose escalation for localized prostate cancer: Substantial benefit observed with 3D conformal therapy Int J Radiat Oncol Biol Phys 57 2003 384 390 (Pubitemid 37040934)
18. M. Roach 3rd, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
19. M.E. Charlson, P. Pompei, and K.L. Ales A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation J Chronic Dis 40 1987 373 383 (Pubitemid 17055592)
20. T.K. Choueiri, M.H. Chen, and A.V. D'Amico Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death Cancer 116 2010 1887 1892
21. M.K. Buyyounouski, A.L. Hanlon, and E.M. Horwitz Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy Int J Radiat Oncol Biol Phys 70 2008 59 66 (Pubitemid 350251025)
22. J.W. Denham, A. Steigler, and M. Kumar Measuring time to biochemical failure in the TROG 96.01 trial: When should the clock start ticking? Int J Radiat Oncol Biol Phys 75 2009 1008 1012
23. J.W. Denham, A. Steigler, and C. Wilcox Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial Lancet Oncol 9 2008 1058 1068
24. J. Epstein, W. Allsbrook Jr., and M. Amin The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma Am J Surg Pathol 29 2005 1228 1242 (Pubitemid 41232997)
25. P.L. Nguyen, M.H. Chen, and W.J. Catalona Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors Intt J Radiat Oncol Biol Phys 73 2009 659 664
26. N. Stone, L. Potters, and B. Davis Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 73 2009 341 346
27. R. Jacob, A.L. Hanlon, and E.M. Horwitz The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer Cancer 100 2004 538 543 (Pubitemid 38124771)
28. P.B. Morgan, A.L. Hanlon, and E.M. Horwitz Radiation dose and late failures in prostate cancer Int J Radiat Oncol Biol Phys 67 2007 1074 1081
29. P.B. Morgan, A.L. Hanlon, and E.M. Horwitz Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy Cancer 110 2007 68 80 (Pubitemid 46986420)
30. J.M. Crook, S. Malone, and G. Perry Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: Results from a Canadian randomized trial Cancer 115 2009 673 679
31. E. Benaim, C. Pace, and C. Roehrborn Gleason score predicts androgen independent progression after androgen deprivation therapy Eur Urol 42 2002 12 17 (Pubitemid 35339640)
32. Sandler HM, Hunt D, Sartor AO, et al. A phase III protocol of androgen suppression (AS) and radiation therapy (RT) versus AS and RT followed by chemotherapy with paclitaxel, extramustine, and etoposide (TEE) for localized, high-risk, prostate cancer, RTOG 9902. The 2010 ASCO Annual Meeting. Chicago, IL; 2010.
33. S.A. Rosenthal, and H.M. Sandler Treatment strategies for high-risk locally advanced prostate cancer Nat Rev Urol 7 2010 31 38
34. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial Lancet 360 2002 103 108 (Pubitemid 34786197)
35. M. Bolla, T. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
36. E. Horwitz, K. Bae, and G. Hanks Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 2497 2504
37. M. Pilepich, K. Winter, and C. Lawton Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: Long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290 (Pubitemid 40470408)
38. L. Souhami, K. Bae, and M. Pilepich Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: A secondary analysis of RTOG 85-31 J Clin Oncol 27 2009 2137 2143
39. A. Widmark, O. Klepp, and A. Solberg Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial Lancet 373 2009 301 308
40. D.M. Kube, C.D. Savci-Heijink, and A.F. Lamblin Optimization of laser capture microdissection and RNA amplification for gene expression profiling of prostate cancer BMC Mol Biol 8 2007 25
41. T.A. Stamey, J.A. Warrington, and M.C. Caldwell Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia J Urol 166 2001 2171 2177 (Pubitemid 33065250)
42. S.A. Tomlins, R. Mehra, and D.R. Rhodes Integrative molecular concept modeling of prostate cancer progression Nat Genet 39 2007 41 51 (Pubitemid 46026500)
43. L. True, I. Coleman, and S. Hawley A molecular correlate to the Gleason grading system for prostate adenocarcinoma Proc Natl Acad Sci U S A 103 2006 10991 10996 (Pubitemid 44148406)
44. J. Lapointe, C. Li, and J.P. Higgins Gene expression profiling identifies clinically relevant subtypes of prostate cancer Proc Natl Acad Sci U S A 101 2004 811 816 (Pubitemid 38121040)
45. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell;18:11-22.
46. A. Partin, M. Kattan, and E. Subong Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update JAMA 277 1997 1445 1451 (Pubitemid 27208886)
47. M. Cooperberg, D. Pasta, and E. Elkin The University of California, San Francisco Cancer of the Prostate Risk Assessment Score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy J Urol 173 2005 1938 1942 (Pubitemid 40675216)
48. M. Kattan, T. Wheeler, and P. Scardino Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer J Clin Oncol 17 1999 1499 1507 (Pubitemid 29220858)
49. M. Kattan, M. Zelefsky, and P. Kupelian Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer J Clin Oncol 18 2000 3352 3359
50. A. Stephenson, P. Scardino, and J. Eastham Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy J Clin Oncol 23 2005 7005 7012